Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NSCLC × Afatinib × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 52 Neoplasms 21 Squamous Cell Carcinoma of Head and Neck 12 Lung Neoplasms 10 Head and Neck Neoplasms 10 Breast Neoplasms 10 Neoplasm Metastasis 8 Carcinoma, Squamous Cell 5 Stomach Neoplasms 4 Pancreatic Neoplasms 4 Esophageal Squamous Cell Carcinoma 4 Prostatic Neoplasms 3 Glioblastoma 3 Esophageal Neoplasms 3 Colorectal Neoplasms 3 Adenocarcinoma 3 Solid Tumors 2 Non-small-cell Lung Cancer With Somatic EGFR Mutations 2 Brain Neoplasms 2 Adenocarcinoma of Lung 2 Urologic Neoplasms 1 Urinary Bladder Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Triple Negative Breast Neoplasms 1 Thrombocytosis 1 Thoracic Neoplasms 1 Squamous Non-small Cell Lung Cancer 1 Squamous Cell Cancers of the Head and Neck 1 Small Cell Lung Carcinoma 1

Interventions

osimertinib 11 Pemetrexed 10 Carboplatin 10 aflutinib 8 Gefitinib 7 Drug Therapy 7 Radiotherapy 6 anlotinib 5 Docetaxel 5 Cisplatin 5 pembrolizumab 4 icotinib 4 Vinorelbine 4 Radiosurgery 4 Paclitaxel 4 Gemcitabine 4 Erlotinib Hydrochloride 4 tislelizumab 3 apatinib 3 HM781-36B 3 toripalimab 2 spartalizumab 2 dacomitinib 2 camrelizumab 2 Tyrosine Kinase Inhibitors 2 Thalidomide 2 Surgical Procedures, Operative 2 S 1 (combination) 2 Platinum 2 Immune Checkpoint Inhibitors 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04575415 2020-10-20

BELLA

Guangdong Association of Clinical Trials

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡